✦ LIBER ✦

Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain

✍ Scribed by Harmon J Eyre; Joel D Ohlsen; Jess Frank; Albert F LoBuglio; Joseph D McCracken; T J Weatherall; C M Mansfield

Publisher: Springer US
Year: 1984
Tongue: English
Weight: 358 KB
Volume: 2
Category: Article
ISSN: 0167-594X
DOI: 10.1007/bf00178115

No coin nor oath required. For personal study only.

✦ Synopsis

One hundred sixteen eligible patients with metastatic cancer to the brain were randomized to receive either radiotherapy 3000 rad/!0 fractions (treatment l) or the same radiotherapy plus metronidazole 6 gm/m 2 (treatment 2). One hundred eleven patients were either fully or partially evaluable. The response rates (CR + PR) and survival showed no significant differences between treatments. Treatment 1: CR + PR 24%, median survival 14 weeks, Treatment 2: CR + PR 27%, median survival 12 weeks. There were no differences observed in response rates based on primary tumor site, neurologic performance status, or extent of metastatic disease. Metronidazole therapy was associated with substantial nausea and vomiting but no neurotoxicity was observed. Oral metronidazole given every other day during radiation therapy provided no clinical benefit for patients with brain metastases compared to radiotherapy alone.

📜 SIMILAR VOLUMES

A randomized phase 2 trial comparing 3-h

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

✍ Stacy L. Moulder; Frankie A. Holmes; Anthony W. Tolcher; Peter Thall; Kristine B 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

## Abstract ## BACKGROUND: This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3‐hour versus 96‐hour infusion schedules. ## METHODS: Patients with metastatic breast cancer (MBC) were randomly assigned to receive paclitaxel starting at a dose of 250 mg/m^2^ intr

Quality of life, mucositis, and xerostom

Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis

✍ Graeme G. Duncan; Joel B. Epstein; Dongsheng Tu; Samy El Sayed; Andrea Bezjak; J 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract ## Background. The National Cancer Institute of Canada Clinical Trials Group undertook a multicenter, randomized, double‐blind controlled trial of an oral antimicrobial versus placebo to prevent and treat mucositis. We present the quality of life (QOL) analysis for this trial. ## Meth

Comparison of the efficacy and safety of

Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis : A prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer

✍ Rene-Jean Bensadoun; Jamel Daoud; Brahim El Gueddari; Laurent Bastit; Rene Gourm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 2 views

## Abstract ## BACKGROUND. Topical antifungal treatments are recommended but rarely used as first‐line therapy for oropharyngeal candidiasis (OPC) in patients with cancer. Miconazole Lauriad 50‐mg mucoadhesive buccal tablet (MBT) Loramyc reportedly delivered rapid and prolonged, effective concentr